(MENAFN- EIN Presswire) EINPresswire/ -- Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

What Is The Estimated Industry Size Of Pseudomonas Aeruginosa Infection Treatment Market?
Recently, the market size for treatment of pseudomonas aeruginosa infection has experienced a solid growth. It is projected to expand from a value of $2.45 billion in 2024 to $2.65 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.0%. A surge in nosocomial infections, growing awareness about antibiotic resistance, a rise in healthcare spending, the growth and development of healthcare and hospital facilities, as well as an emphasis on early diagnosis and intervention, are all contributing factors to the growth experienced in the historic period.

It is anticipated that the market size for the treatment of pseudomonas aeruginosa infection will experience significant expansion in the next few years. The market is set to reach ""$3.61 billion by 2029, with a compound annual growth rate (CAGR) of 8.1%. The growth during this forecasted period is credited to the increasing studies on antimicrobial peptides, emphasis on treatment efficacy and safety, escalation in the number of multidrug-resistant paeruginosa cases, the patient-focused approach to treatment creation, and regulatory incentives. Key trends to watch for during this forecasted period are combination therapies, progression in drug delivery, point-of-care diagnostics, the incorporation of genomic data into treatment plans, and international cooperation in antibiotic research.

Download a free sample of the pseudomonas aeruginosa infection treatment market report:

What Are The Major Factors Driving The Pseudomonas Aeruginosa Infection Treatment Global Market Growth?
The escalation in comorbidity cases, including pneumonia, cystic fibrosis, urinary tract infections, and bloodstream infections is set to bolster the upward trajectory of the pseudomonas aeruginosa infection treatment market. Comorbidity pertains to the simultaneous existence of multiple medical conditions, often of a chronic nature, impacting either the physical or mental wellbeing. An August 2022 article by the National Library of Medicine, a US-based biomedical library and a hub for computational biology and biomedical informatics, revealed community-acquired pneumonia in the US occurs at a rate of 24.8 instances per 10,000 adults annually, with a noted increase with age progression. Being the eighth most common cause of death and the topmost infectious fatality cause, pneumonia records a staggering death rate of 23% among patients admitted to the intensive care unit. Hence, the rising incidence of co-morbidities, namely pneumonia, cystic fibrosis, urinary tract infections, and bloodstream infections, fuels the expansion of the pseudomonas aeruginosa infection treatment market.

Who Are The Leading Companies In The Pseudomonas Aeruginosa Infection Treatment Market?
Major players in the Pseudomonas Aeruginosa Infection Treatment include:
. AbbVie Inc.
. Teva Pharmaceutical Industries Ltd.
. Merck & Co Inc.
. Janssen Pharmaceutica NV
. Pfizer Inc.
. Lupin Limited
. AstraZeneca plc
. Bristol Myers Squibb Company
. Gilead Sciences Inc.
. Novartis Pharmaceuticals Corporation

What Are The Prominent Trends In The Pseudomonas Aeruginosa Infection Treatment Market?
Top companies in the pseudomonas aeruginosa infection treatment industry are resorting to personalized or targeted treatments, such as precision antibiotic therapies, to maintain their dominance. Precision antibiotic therapies are tailored therapies that leverage engineered proteins, known as bacteriocins, to combat antibiotic-resistant bacteria aggressively. For instance, Glox Therapeutics Ltd., a Scottish pharmaceutical firm, in November 2023, secured seed funding of $5.25 million (£4.3 million) to embark on the development of precision antibiotic therapies. These therapies are designed using bacteriocins, which are naturally occurring antimicrobial proteins, to target antibiotic-resistant bacteria. The funding will aid in setting up laboratories in Oxford and Glasgow and constituting a larger research team. Glox's research lays emphasis on combating resistant Gram-negative pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae, which are a significant part of the worldwide antimicrobial resistance crisis, responsible for 1.27 million deaths every year.

What Are The Primary Segments Covered In The Global Pseudomonas Aeruginosa Infection Treatment Market Report?
The pseudomonas aeruginosa infection treatment market covered in this report is segmented –

1) By Medication: Monotherapy, Combination Therapy
2) By Drug Class: Aminoglycoside, Cephalosporin, Carbapenem, Monobactum, Other Drug Classes
3) By Route Of Administration: Nasal, Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Monotherapy: Antibiotics, Antipseudomonal Agents
2) By Combination Therapy: Beta-lactam And Aminoglycoside Combinations, Beta-lactam And Fluoroquinolone Combinations, Other Combinations

View the full pseudomonas aeruginosa infection treatment market report:

Which Region Is Forecasted To Grow The Fastest In The Pseudomonas Aeruginosa Infection Treatment Industry?
In 2024, Europe stood as the leading region in the market for pseudomonas aeruginosa infection treatment. It is anticipated that the fastest-growing region will be North America during the forecast period. The geographical scopes of the pseudomonas aeruginosa infection treatment market report encompass Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Pseudomonas Aeruginosa Infection Treatment Market 2025, By The Business Research Company

Ent Devices Global Market Report 2025

Nasal Splints Global Market Report 2025

Cough And Cold Preparations Global Market Report 2025

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...
The Business Research Company -

Follow Us On:
LinkedIn:

MENAFN23112025003118003196ID1110386228